Bullfrog AI Holdings, Inc. Form 8-K Summary
Business Context and Reporting Period
Bullfrog AI Holdings, Inc. filed a Current Report on Form 8-K dated September 13, 2023, with the report signed September 14, 2023. The company is an emerging growth company, and its common stock and tradeable warrants are listed on Nasdaq under BFRG and BFRGW, respectively.
Material Agreement
On September 8, 2023, the company entered into a data use and technology partnership agreement with the Lieber Institute for Brain Development (LIBD). The exhibit describes the agreement as dated September 7, 2023.
- Bullfrog AI may use its bfLEAP platform to analyze LIBD brain data, including transcriptomic, genomic, DNA methylation, cell-line, clinical, and imaging data.
- The arrangement is exclusive for one year and may be extended.
- The license is fully paid and royalty-free.
- The parties contemplate a future commercialization agreement involving commercialization of the data and revenue sharing.
Financial Metrics and Liquidity
This 8-K does not provide revenue, profit or loss, cash flow, margins, debt, cash balance, liquidity, capital expenditures, or other financial statement metrics. The filing text does not provide a clear estimate of the agreement’s financial impact.
Changes, Outlook, and Risks
The partnership expands the company’s access to specialized brain-related datasets and may support identification of previously unrecognized relationships through the bfLEAP platform. However, any commercialization agreement, revenue generation, or revenue-sharing arrangement remains prospective and is not guaranteed by this filing.
The filing provides no formal financial guidance, operating forecast, or quantified outlook. Key uncertainties include the ability to generate useful results from the data, the potential extension of the exclusive arrangement, execution of a commercialization agreement, and the timing and amount of any resulting revenue.
The company also furnished a September 13, 2023 press release under Regulation FD, but the press release’s substantive contents are not included in the provided filing text.
Important Facts to Verify
- Review Exhibit 10.1 for the complete exclusivity, data-use, termination, confidentiality, and commercialization terms.
- Confirm the effective date, because the filing references September 8 while the exhibit is identified as dated September 7, 2023.
- Determine whether a commercialization agreement is ultimately executed and whether it specifies revenue sharing or other consideration.
- Assess subsequent filings for measurable revenue, costs, cash needs, or other financial effects from the LIBD relationship.
- Review Exhibit 99.1 separately because its full contents are not provided here.